Adult and Adolescent Vaccines Market to 2018 – Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth

Publisher Name :
Date: 8-Apr-2013
No. of pages: 119

The leading business intelligence provider GBI Research has released its latest research report, entitled “Adult and Adolescent Vaccines Market to 2018 Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth”. The report provides insights into the vaccines in the adult and adolescent vaccines market, including market forecasts up to 2018. It provides an in-depth analysis of the vaccines for the adult and adolescent market, as well as insights into the adult and adolescent vaccines market’s Research and Development (R&D) pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global adult and adolescent vaccines market. The report analyzes the market for adult and adolescent vaccines in the US, and the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. The report discusses the global pipeline for adult and adolescent vaccines across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research found that the adult and adolescent vaccines market in the top seven markets was valued at $7.2 billion in 2011, increasing at a Compound Annual Growth Rate (CAGR) of 6.9% during the 2007–2011 historic period. The market is projected to witness a growth of 5.6% during the 2011–2018 forecast period to reach $10.5 billion. The growth in the adult and adolescent vaccines market is driven by increased uptake of pneumococcal vaccines such as Prevnar 13 which got approved for use in people aged 50 and older. The pneumococcal vaccines market is expected to grow at a CAGR of 19% during the forecast period and reach $1.7 billion in 2018, from $0.5 billion in 2011.

Scope

  • Annualized market data for the adult and adolescent vaccines market from 2007 to 2011, forecast forward to 2018
  • Analysis of the adult and adolescent vaccines market in the leading geographies of the world, which includes the US, the UK, Germany, France, Italy, Spain, and Japan
  • Market characterization of the adult and adolescent vaccines market including market size and cost of vaccination
  • Key drivers and barriers that have a significant impact on the market
  • Coverage of pipeline molecules in various phases of vaccine development
  • Competitive benchmarking of leading companies. Key companies studied in this report are GlaxoSmithKline, Sanofi, Pfizer, Merck and Novartis.
  • Key M&A activities and licensing agreements that have taken place between 2009 and up to November 2012 in the global adult and adolescent vaccines market.

Reasons to buy

  • Align your product portfolio to the markets with the highest growth potential
  • Develop market-entry and market expansion strategies by identifying the potential regions and adult and adolescent vaccines market segments poised for strong growth
  • Create a more specifically-tailored country strategy through the understanding of key drivers and barriers of the global adult and adolescent vaccines market
  • Develop key strategic initiatives by understanding the key focus areas and top-selling products of leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Adult and Adolescent Vaccines Market to 2018 – Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth

Table of Contents

1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 12

2 Adult and Adolescent Vaccines Market to 2018 - Introduction 14
2.1 Overview 14

3 Adult and Adolescent Vaccines Market to 2018 - Overview 15
3.1 Vaccine Preventable Diseases 15
3.1.1 Types of Vaccines 16
3.2 Recommendations for Immunization 17
3.2.1 The US 17
3.2.2 Top Five European Countries 19
3.2.3 Japan 20
3.3 Regulatory Framework 21
3.3.1 The US 21
3.3.2 Top Five European Countries 22
3.3.3 Japan 23
3.4 Vaccine Manufacturing Process 24

4 Adult and Adolescent Vaccines Market to 2018 - Market Characterization and Forecast 25
4.1 Revenue Forecast 25
4.2 Market Share by Type of Vaccines 27
4.3 Market Share by Geography 28
4.4 Drivers 28
4.4.1 Adult Vaccines Segment to Drive Future Growth 28
4.4.2 High Unmet Needs 28
4.4.3 Targeting New Diseases Areas for Vaccines Likely To Drive the Market 29
4.4.4 Novel Vaccine Technologies 29
4.5 Restraints 30
4.5.1 Production Capacity Limitations 30
4.5.2 High Initial Capital Investments and Technical Expertise 30
4.5.3 Regulations Delay Vaccine Launch and Acceptance 30

5 Adult and Adolescent Vaccines Market to 2018 - Influenza Vaccines 31
5.1 Disease Overview 31
5.2 Market Forecasts 32
5.2.1 The US 32
5.2.2 Top Five European Countries 34
5.2.3 Japan 36
5.3 Cost of Vaccination 37
5.3.1 The US 37
5.3.2 Top Five European Countries 37
5.3.3 Japan 38
5.4 Pipeline Analysis - Influenza Vaccines 39

6 Adult and Adolescent Vaccines Market to 2018 - Tetanus, Diphtheria and Pertussis Vaccines 42
6.1 Disease Overview 42
6.2 Market Forecasts 43
6.2.1 The US 43
6.2.2 Top Five European Countries 44
6.2.3 Japan 46
6.3 Cost of Vaccination 47
6.3.1 The US 47
6.3.2 Top Five European Countries 47
6.3.3 Japan 48
6.4 Pipeline Analysis - Tetanus, Diphtheria, Pertussis (Td/Tdap) Vaccines 49

7 Adult and Adolescent Vaccines Market to 2018 - Pneumococcal Vaccines 50
7.1 Disease Overview 50
7.2 Market Forecasts 51
7.2.1 The US 51
7.2.2 Top Five European Countries 53
7.2.3 Japan 55
7.3 Cost of Vaccination 56
7.3.1 The US 56
7.3.2 Top Five European Countries 56
7.3.3 Japan 57
7.4 Pipeline Analysis - Pneumococcal Vaccines 58

8 Adult and Adolescent Vaccines Market to 2018 - Meningococcal Vaccines 60
8.1 Disease Overview 60
8.2 Market Forecasts 61
8.2.1 The US 61
8.2.2 Top Five European Countries 62
8.3 Cost of Vaccination 64
8.3.1 The US 64
8.3.2 Top Five European Countries 64
8.4 Pipeline Analysis - Meningococcal Vaccines 65

9 Adult and Adolescent Vaccines Market to 2018 - Human Papilloma Virus Vaccines 66
9.1 Disease Overview 66
9.2 Market Forecasts 67
9.2.1 The US 67
9.2.2 Top Five European Countries 68
9.2.3 Japan 70
9.3 Cost of Vaccination 71
9.3.1 The US 71
9.3.2 Top Five European Countries 71
9.3.3 Japan 72
9.4 Pipeline Analysis - Human Papillomavirus Vaccines 73

10 Adult and Adolescent Vaccines Market to 2018 - Hepatitis Vaccines 75
10.1 Disease Overview 75
10.2 Market Forecasts 76
10.2.1 The US 76
10.2.2 Top Five European Countries 77
10.2.3 Japan 79
10.3 Cost of Vaccination 80
10.3.1 The US 80
10.3.2 Top Five European Countries 80
10.3.3 Japan 81
10.4 Pipeline Analysis - Hepatitis Vaccines 82

11 Adult and Adolescent Vaccines Market to 2018 - Measles, Mumps and Rubella Vaccines 85
11.1 Disease Overview 85
11.2 Market Forecasts 85
11.2.1 The US 85
11.2.2 Top Five European Countries 87
11.3 Cost of Vaccination 88
11.3.1 The US 88
11.3.2 Top Five European Countries 89

12 Adult and Adolescent Vaccines Market to 2018 - Zoster Vaccines 90
12.1 Disease Overview 90
12.2 Market Forecasts 90
12.2.1 The US 90
12.2.2 The UK 91
12.3 Cost of Vaccination 91
12.3.1 The US 91
12.3.2 The UK 92
12.4 Pipeline Analysis - Zoster Vaccines 92

13 Adult and Adolescent Vaccines Market to 2018 - Varicella Vaccines 93
13.1 Disease Overview 93
13.2 Market Forecasts 93
13.2.1 The US 93
13.2.2 Top Five European Countries 94
13.2.3 Japan 96
13.3 Cost of Vaccination 97
13.3.1 The US 97
13.3.2 Top Five European Countries 97
13.3.3 Japan 98
13.4 Pipeline Analysis - Varicella Vaccines 98

14 Adult and Adolescent Vaccines Market to 2018 - Competitive Landscape 99
14.1 Introduction 99
14.2 Major Company Profiles 99
14.2.1 GlaxoSmithKline 99
14.2.2 Sanofi 101
14.2.3 Pfizer 102
14.2.4 Merck 103
14.2.5 Novartis 104

15 Adult and Adolescent Vaccines Market to 2018 - Strategic Consolidations 105
15.1 Deals by Year 105
15.2 Deals by Type 106
15.3 Deals by Value 107
15.4 Deals by Geography 108
15.5 Summary of Major M&A Deals 109
15.6 Summary of Major Licensing Deals 110
15.7 Summary of Major Partnerships 111

16 Adult and Adolescent Vaccines Market to 2018 - Appendix 113
16.1 Market Definitions 113
16.2 Abbreviations 113
16.3 Bibliography 115
16.4 Research Methodology 115
16.4.1 Coverage 115
16.4.2 Secondary Research 116
16.4.3 Primary Research 116
16.4.4 Model for Estimation of Vaccine Market 117
16.5 Geographical Landscape 119
16.6 Pipeline Analysis 119
16.7 Competitive Landscape 119
16.7.1 Expert Panel Validation 119
16.8 Contact Us 119
16.9 Disclaimer 119

List of Tables

Table 1: Adult and Adolescent Vaccines Market to 2018, Vaccine-preventable Diseases, 2012 15
Table 2: Adult and Adolescent Vaccines Market to 2018, Top Seven Markets, Revenue ($bn), 2007-2011 25
Table 3: Adult and Adolescent Vaccines Market to 2018, Top Seven Markets, Revenue Forecast ($bn), 2011-2018 26
Table 4: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, the US, Revenue ($m), 2007-2011 33
Table 5: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, The US, Revenue Forecast ($m), 2011-2018 33
Table 6: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Top Five European Countries, Revenue ($m), 2007-2011 34
Table 7: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011-2018 35
Table 8: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Japan, Revenue ($m), 2007-2011 36
Table 9: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Japan, Revenue Forecast ($m), 2011-2018 36
Table 10: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, the US, Cost of Vaccination ($), 2007-2011 37
Table 11: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, the US, Cost of Vaccination Forecast ($), 2011-2018 37
Table 12: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007-2011 37
Table 13: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011-2018 37
Table 14: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Japan, Cost of Vaccination ($), 2007-2011 38
Table 15: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Japan, Cost of Vaccination Forecast ($), 2011-2018 38
Table 16: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Global, Pipeline by Phase, 2012 40
Table 17: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, the US, Revenue ($m), 2007-2011 43
Table 18: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, the US, Revenue Forecast ($m), 2011-2018 43
Table 19: Adult and Adolescent Vaccines Market to 2018, Td/ Tdap, Top Five European Countries, Revenue ($m), 2007-2011 44
Table 20: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Top Five European Countries, Revenue Forecast ($m), 2011-2018 45
Table 21: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Japan, Revenue ($m), 2007-2011 46
Table 22: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Japan, Revenue Forecast ($m), 2011-2018 46
Table 23: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, the US, Cost of Vaccination ($), 2007-2011 47
Table 24: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, the US, Cost of Vaccination Forecast ($), 2011-2018 47
Table 25: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Top Five European Countries, Cost of Vaccination ($), 2007-2011 47
Table 26: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Top Five European Countries, Cost of Vaccination Forecast ($), 2011-2018 47
Table 27: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Japan, Cost of Vaccination ($), 2007-2011 48
Table 28: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Japan, Cost of Vaccination Forecast ($), 2011-2018 48
Table 29: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Global, Pipeline by Phase, 2012 49
Table 30: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, the US, Revenue ($m), 2007-2011 51
Table 31: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, the US, Revenue Forecast ($m), 2011-2018 51
Table 32: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Top Five European Countries, Revenue ($m), 2007-2011 53
Table 33: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011-2018 54
Table 34: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Japan, Revenue ($m), 2007-2011 55
Table 35: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Japan, Revenue Forecast ($m), 2011-2018 55
Table 36: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, the US, Cost of Vaccination ($), 2007-2011 56
Table 37: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, the US, Cost of Vaccination Forecast ($), 2011-2018 56
Table 38: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007-2011 56
Table 39: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011-2018 56
Table 40: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Japan, Cost of Vaccination ($), 2007-2011 57
Table 41: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Japan, Cost of Vaccination Forecast ($), 2011-2018 57
Table 42: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Global, Pipeline by Phase, 2012 59
Table 43: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, the US, Revenue ($m), 2007-2011 61
Table 44: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, the US, Revenue Forecast ($m), 2011-2018 61
Table 45: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Top Five European Countries, Revenue ($m), 2007-2011 62
Table 46: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011-2018 63
Table 47: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, the US, Cost of Vaccination ($), 2007-2011 64
Table 48: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, the US, Cost of Vaccination Forecast ($), 2011-2018 64
Table 49: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007-2011 64
Table 50: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011-2018 64
Table 51: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Global, Pipeline by Phase, 2012 65
Table 52: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, the US, Revenue ($m), 2007-2011 67
Table 53: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, the US, Revenue Forecast ($m), 2011-2018 67
Table 54: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Top Five European Countries, Revenue ($m), 2007-2011 68
Table 55: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011-2018 69
Table 56: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Japan, Revenue Forecast ($m), 2010-2018 70
Table 57: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, the US, Cost of Vaccination ($), 2007-2011 71
Table 58: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, the US, Cost of Vaccination Forecast ($), 2011-2018 71
Table 59: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007-2011 71
Table 60: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011-2018 71
Table 61: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Japan, Cost of Vaccination Forecast ($), 2009-2018 72
Table 62: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Global, Pipeline by Phase (%), 2012 74
Table 63: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, the US, Revenue ($m), 2007-2011 76
Table 64: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, the US, Revenue Forecast ($m), 2011-2018 76
Table 65: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Top Five European Countries, Revenue ($m), 2007-2011 77
Table 66: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011-2018 78
Table 67: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Japan, Revenue ($m), 2007-2011 79
Table 68: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Japan, Revenue Forecast ($m), 2011-2018 79
Table 69: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, the US, Cost of Vaccination ($), 2007-2011 80
Table 70: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, the US, Cost of Vaccination Forecast ($), 2011-2018 80
Table 71: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007-2011 80
Table 72: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011-2018 80
Table 73: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Japan, Cost of Vaccination ($), 2007-2011 81
Table 74: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Japan, Cost of Vaccination Forecast ($), 2011-2018 81
Table 75: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Global, Pipeline by Phase, 2012 83
Table 76: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, the US, Revenue ($m), 2007-2011 86
Table 77: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, the US, Revenue Forecast ($m), 2011-2018 86
Table 78: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Top Five European Countries, Revenue ($m), 2007-2011 87
Table 79: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011-2018 88
Table 80: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, the US, Cost of Vaccination ($), 2007-2011 88
Table 81: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, the US, Cost of Vaccination Forecast ($), 2011-2018 88
Table 82: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007-2011 89
Table 83: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011-2018 89
Table 84: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the US, Revenue ($m), 2007-2011 91
Table 85: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the US, Revenue Forecast ($m), 2011-2018 91
Table 86: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the UK, Revenue Forecast ($m), 2011-2018 91
Table 87: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the US, Cost of Vaccination ($), 2007-2011 91
Table 88: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the US, Cost of Vaccination Forecast ($), 2011-2018 91
Table 89: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the UK, Cost of Vaccination Forecast ($), 2012-2018 92
Table 90: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, Global, Pipeline by Phase, 2012 92
Table 91: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, the US, Revenue ($m), 2007-2011 94
Table 92: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, the US, Revenue Forecast ($m), 2011-2018 94
Table 93: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Top Five European Countries, Revenue ($m), 2007-2011 95
Table 94: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011-2018 95
Table 95: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Japan, Revenue ($m), 2007-2011 96
Table 96: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Japan, Revenue Forecast ($m), 2011-2018 96
Table 97: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, the US, Cost of Vaccination ($), 2007-2011 97
Table 98: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, the US, Cost of Vaccination Forecast ($), 2011-2018 97
Table 99: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007-2011 97
Table 100: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011-2018 97
Table 101: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Japan, Cost of Vaccination ($), 2007-2011 98
Table 102: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011-2018 98
Table 103: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Global, Pipeline by Phase, 2012 98

List of Figures

Figure 1: Adult and Adolescent Vaccines Market to 2018, Global, Types of Vaccines, 2012 16
Figure 2: Adult and Adolescent Vaccines Market to 2018, The US, Recommendations for Immunization (19-65+ Years), 2012 17
Figure 3: Adult and Adolescent Vaccines Market to 2018, the US, Recommendations for Immunization (7-18 Years), 2012 18
Figure 4: Adult and Adolescent Vaccines Market to 2018, Top Five European Countries, Recommendations for Immunization, 2012 19
Figure 5: Adult and Adolescent Vaccines Market to 2018, Japan, Recommendations for Immunization (Under 20 Years of Age), 2011 20
Figure 6: Adult and Adolescent Vaccines Market to 2018, Global, Vaccine Manufacturing Process, 2012 24
Figure 7: Adult and Adolescent Vaccines Market to 2018, Top Seven Markets, Revenue Forecast ($bn), 2007-2018 25
Figure 8: Adult and Adolescent Vaccines Market to 2018, Top Seven Markets, Market Share by Type of Vaccines (%), 2011 27
Figure 9: Adult and Adolescent Vaccines Market to 2018, Top Seven Markets, Market Share by Geography (%), 2011 28
Figure 10: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, the US, Revenue Forecast ($m), 2007-2018 32
Figure 11: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007-2018 34
Figure 12: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Japan, Revenue Forecast ($m), 2007-2018 36
Figure 13: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Global, Pipeline by Phase (%), 2012 39
Figure 14: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, the US, Revenue Forecast ($m), 2007-2018 43
Figure 15: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Top Five European Countries, Revenue Forecast ($m), 2007-2018 44
Figure 16: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Japan, Revenue Forecast ($m), 2007-2018 46
Figure 17: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Global, Pipeline by Phase (%), 2012 49
Figure 18: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, the US, Revenue Forecast ($m), 2007-2018 51
Figure 19: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007-2018 53
Figure 20: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Japan, Revenue Forecast ($m), 2007-2018 55
Figure 21: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Global, Pipeline by Phase (%), 2012 58
Figure 22: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, the US, Revenue Forecast ($m), 2007-2018 61
Figure 23: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007-2018 62
Figure 24: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Global, Pipeline by Phase (%), 2012 65
Figure 25: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, the US, Revenue Forecast ($m), 2007-2018 67
Figure 26: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007-2018 68
Figure 27: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Japan, Revenue Forecast ($m), 2010-2018 70
Figure 28: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Global, Pipeline by Phase (%), 2012 73
Figure 29: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, the US, Revenue Forecast ($m), 2007-2018 76
Figure 30: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007-2018 77
Figure 31: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Japan, Revenue Forecast ($m), 2007-2018 79
Figure 32: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Global, Pipeline by Phase (%), 2012 82
Figure 33: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, the US, Revenue Forecast ($m), 2007-2018 86
Figure 34: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007-2018 87
Figure 35: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the US, Revenue Forecast ($m), 2007-2018 90
Figure 36: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, Global, Pipeline by Phase (%), 2012 92
Figure 37: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, the US, Revenue Forecast ($m), 2007-2018 93
Figure 38: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007-2018 94
Figure 39: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Japan, Revenue Forecast ($m), 2007-2018 96
Figure 40: Adult and Adolescent Vaccines Market to 2018, GSK, SWOT Analysis, 2012 100
Figure 41: Adult and Adolescent Vaccines Market to 2018, Sanofi, SWOT Analysis, 2012 101
Figure 42: Adult and Adolescent Vaccines Market to 2018, Pfizer, SWOT Analysis, 2012 102
Figure 43: Adult and Adolescent Vaccines Market to 2018, Merck, SWOT Analysis, 2012 103
Figure 44: Adult and Adolescent Vaccines Market to 2018, Novartis, SWOT Analysis, 2012 104
Figure 45: Adult and Adolescent Vaccines Market to 2018, Global, Strategic Consolidations, Deals by Year, 2009-2012 105
Figure 46: Adult and Adolescent Vaccines Market to 2018, Global, Strategic Consolidations, Deals by Type, 2009-2012 106
Figure 47: Adult and Adolescent Vaccines Market to 2018, Global, Strategic Consolidations, Deals by Value, 2009-2012 107
Figure 48: Adult and Adolescent Vaccines Market to 2018, Global, Strategic Consolidations, Deals by Geography, 2009-2012 108
Figure 49: GBI Research Market Forecasting Model 118

  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Growth in the Indian Watch Industry
    Earlier, in India watches were seen as a luxury item. However, watches are now witnessing a fundamental change in perception, and are now gaining respect as an essential utility item. With the liberalization of the Indian market, coupled with the rising purchasing power of the young and consumerist Indians, watch industry in India seems to [...]
  • Global Retail Ready Packaging Market to Witness Steady Growth
    The market for retail ready packaging has witnessed impressive growth in recent years with boom in the retail industry. Retail ready packaging, also known as shelf-ready packaging is designed for the retail outlet, ready to be placed on shelf without any need for unpacking or repacking. In 2011, the global market for retail packaging was [...]
  • Global Hypertension Drugs Market 2014-2018
    Published: 4-Apr-2014        Price: US $2500 Onwards        Pages: 65
    Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. TechNavio's analysts forecas......
  • EpiCast Report: Allergic Rhinitis – Epidemiology Forecast to 2023
    Published: 1-Apr-2014        Price: US $3995 Onwards        Pages: 49
    Allergic rhinitis is a chronic respiratory disease characterized by inflammation of the nasal cavity and affects people of all ages. The main symptoms of allergic rhinitis are sneezing, nasal itching, blocked or runny nose and sore throat. Research suggests that a combination of genetic factors such as family history of allergic rhinitis and environmental factors such as exposure to allergens, including smoke, dust, pollen, insects, molds, or animal dander, may increase the risk for developing a......
  • Perennial Allergic Rhinitis – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 69
    Perennial Allergic Rhinitis - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Perennial Allergic Rhinitis - Pipeline Review, H1 2014', provides an overview of the Perennial Allergic Rhinitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Perennial Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and mole......
  • Tourette Syndrome – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 79
    Tourette Syndrome - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Tourette Syndrome - Pipeline Review, H1 2014', provides an overview of the Tourette Syndrome's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, an......
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 75
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2014', provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug t......
  • Dementia Associated With Alzheimer’s Disease – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 52
    Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2014', provides an overview of the Dementia Associated With Alzheimer's Disease's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dementia Associated With Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug targe......
  • Chronic Back Pain – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 64
    Chronic Back Pain - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Chronic Back Pain - Pipeline Review, H1 2014', provides an overview of the Chronic Back Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, an......
  • Binge Eating Disorder – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 56
    Binge Eating Disorder - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Binge Eating Disorder - Pipeline Review, H1 2014', provides an overview of the Binge Eating Disorder's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with la......
  • Lewy body Dementia – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 39
    Lewy body Dementia - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Lewy body Dementia - Pipeline Review, H1 2014', provides an overview of the Lewy body Dementia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Lewy body Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs